tafinlar
novartis europharm limited - dabrafenib mesilate - melanoma - Æxlishemjandi lyf - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. viðbótar meðferð melanomadabrafenib ásamt trametinib er ætlað til viðbótar meðferð fullorðinn sjúklinga með stigi iii húðkrabbanum með meÐferÐ v600 stökkbreyting, eftir fylltu brottnám. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.
contalgin uno hart forðahylki 90 mg
mundipharma a/s - morphini sulfas - hart forðahylki - 90 mg
contalgin uno hart forðahylki 30 mg
mundipharma a/s - morphini sulfas - hart forðahylki - 30 mg
contalgin forðatafla 60 mg
mundipharma a/s - morphini sulfas - forðatafla - 60 mg
contalgin forðatafla 5 mg
mundipharma a/s - morphini sulfas - forðatafla - 5 mg
contalgin forðatafla 30 mg
mundipharma a/s - morphini sulfas - forðatafla - 30 mg
contalgin forðatafla 200 mg
mundipharma a/s - morphini sulfas - forðatafla - 200 mg
contalgin forðatafla 100 mg
mundipharma a/s - morphini sulfas - forðatafla - 100 mg
contalgin forðatafla 10 mg
mundipharma a/s - morphini sulfas - forðatafla - 10 mg
abstral tungurótartafla 400 míkróg
kyowa kirin holdings b.v. - fentanylum cítrat - tungurótartafla - 400 míkróg